This article reviews many of the key incretin clinical trials, with a focus on the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors compared with placebo and other glucose-lowering agents used as comparators.
The study strongly suggests that calcium exposure should be limited in patients with ESRD on hemodialysis: Ranked "exceptional" from F1000. Faculty of 1000 Medicine